High-Purity Reagents for Selective Nitric Oxide Synthase Inhibition in Inflammation, Immuno-Oncology, and Neurodegenerative Disease Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for iNOS/NOS2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NOS2 Recombinant Protein (iNOS). Full-length and oxygenase domain variants. >95% purity by SDS-PAGE. Sequence Verified. Theoretical MW confirmed. HEK293 expressed, endotoxin <1EU/µg. | View NOS2 Products |
| Gene Delivery | NOS2 Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction. High titer (>10^8 TU/ml). | View NOS2 Products |
| Benchmark Ab | Anti-iNOS/NOS2 Recombinant Antibody. Positive control for target validation and Western blot. | View NOS2 Products |
| Validator | NOS2 siRNA Set (3 targets + 1 control). Sequence verified for knockdown verification and specificity controls. | View NOS2 Products |
| Isoform Panel (nNOS) | NOS1 (nNOS) Recombinant Protein. Neuronal isoform for selectivity counter-screening and off-target liability assessment. HEK293 expressed. | View NOS1 Products |
| Isoform Panel (eNOS) | NOS3 (eNOS) Recombinant Protein. Endothelial isoform for selectivity counter-screening and cardiovascular safety profiling. HEK293 expressed. | View NOS3 Products |
| Arginine Competitor | ARG1 (Arginase-1) Recombinant Protein. Competing enzyme for substrate depletion studies in the tumor microenvironment. High purity (>95%). | View ARG1 Products |
| Pathway Partner | COX-2 (PTGS2) Recombinant Protein. Pro-inflammatory synergy target for combination therapy screening. | View PTGS2 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (iNOS vs nNOS/eNOS) | Human NOS1/NOS2/NOS3 Ortholog Panel available. Sequence-verified, endotoxin-controlled (<1EU/µg) for accurate IC50 profiling across isoforms. >95% purity for precise counter-screening. |
| Dimerization-Dependent Activity | Full-length and domain-truncated mutant constructs available to study monomer-dimer equilibrium and allosteric disruption. Heme-reconstituted, H4B-loaded protein preparations guarantee cofactor saturation for consistent enzymatic activity. |
| Mutant Drug Resistance Profiling | Active site mutant variants (e.g., W366F, H4B-binding mutants) available for mechanism-of-action studies and resistance screening. Custom mutant construction service. |
| Cross-species Toxicology (Cyno / Mouse) | Human / Mouse / Cyno ortholog proteins available with sequence-verified identity and HEK293 expression. |
| False Positives / Off-target Inhibitor Effects | Sequence-verified siRNA and lentivirus included for genetic specificity checks and stable knockdown line generation. |
| Structural Stability in Assays | High purity (>95%) recombinant enzymes, HEK293 expressed (native folding), with endotoxin control. |
| Lack of Controls | Clinical Benchmark Antibodies included for assay standardization. |
| Cellular Target Engagement | Lentivirus premade particles for stable NOS2 expression in macrophage cells; validated for CETSA and cellular uptake studies. |
Live iNOS/NOS2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic focus for iNOS/NOS2 has shifted from non-selective L-arginine analogs (e.g., L-NMMA, 1400W) toward highly selective small molecule inhibitors that spare endothelial NOS (eNOS) to avoid cardiovascular toxicity. First-generation inhibitors struggled with off-target liabilities against eNOS and nNOS, causing hypertension and neurotoxicity, and faced bioavailability and hepatotoxicity challenges in sepsis trials. The current R&D wave targets chronic inflammatory indications—rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis—where sustained iNOS suppression offers disease-modifying potential. Simultaneously, immuno-oncology programs are exploring iNOS inhibition to reverse myeloid-derived suppressor cell (MDSC) immunosuppression and modulate the tumor microenvironment. Next-generation efforts are focusing on allosteric sites, dimerization disruptors, PROTAC degraders, and combination strategies with PD-1/PD-L1 checkpoint inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective Small Molecule Inhibitors | Merck, GlaxoSmithKline, academic consortia | Rheumatoid arthritis, sepsis, chronic inflammation, neurodegeneration | Isoform Selectivity Panel (NOS1/NOS2/NOS3) with SPR/HPLC readouts; need high-purity proteins for IC50 profiling |
| Immuno-Oncology Modulators | Emerging biotech, university labs, oncology consortiums | Solid tumors (TME modulation, MDSC targeting) | Cell-based validation using NOS2 Lentivirus in macrophage lines; need ORF lentivirus for stable reporter lines |
| Targeted Protein Degradation (PROTAC) | Emerging biotech, academic programs | Inflammatory bowel disease, oncology | High-purity NOS2 protein for ternary complex formation assays; degron identification |
| Gene Silencing (RNAi) | Academic / biotech | Autoimmune diseases, inflammation | Knockdown validation using validated siRNA sets; stable knockdown lines |
| Allosteric Modulators | Preclinical biotech, University of Milan | Neurodegeneration (ALS, multiple sclerosis) | Dimerization disruption assays requiring full-length active protein; need full-length NOS2 with cofactor saturation |
| Natural Product Derivatives | Academic research groups | Chronic inflammation | Enzymatic inhibition assay with sequence-verified antigen and endotoxin control |
| Combination Therapy (iNOS + PD-1) | Oncology consortiums | Solid tumors | Cell-based validation and target engagement assays using lentivirus and siRNA |
Key Mutations & Disease Relevance
Three notable mutations in NOS2/iNOS have been identified in clinical and genomic studies:
- rs3730017: A missense variation documented in dbSNP (VAR_024548) associated with altered iNOS function.
- Very early onset inflammatory bowel disease mutation (VAR_022127): Found in patients with very early onset IBD; leads to increased nitric oxide production, suggesting a pathogenic role in hyperinflammatory states.
- Breast cancer somatic mutation (rs769900089, VAR_036302): Identified in a breast cancer sample, highlighting potential involvement in tumor biology.
Additionally, engineered mutants such as W366F and H4B-binding mutants are commonly used in preclinical research to study drug resistance mechanisms and to design next-generation inhibitors with improved selectivity against resistance-conferring variants.